ALEVIAN, INC.

From the company

Alevian is a preclinical-stage biotech developing regenerative therapeutics that target biological mechanisms promoting repair and regeneration. Its lead program, ALE-001, is an engineered recombinant form of GDF11 designed to treat acute ischemic stroke by reducing inflammation, promoting neovascularization, stimulating neurogenesis, and improving functional recovery, with a treatment window extending to 3 days. ALE-001 is progressing toward first-in-human studies, with additional programs in intracerebral hemorrhage, traumatic brain injury, chronic str